Methods for treatment of pain
The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects.
1. A method for the treatment of pain comprising administering to an individual in need thereof an effective dose of N/OFQ via intranasal administration, provided when the pain is a trigeminal nerve-associated pain, the N/OFQ is not co-administered with an oxytocin peptide.
2. The method of claim 1 , wherein said treatment comprises treatment of a trigeminal pain, a somatic pain, a neuropathic pain or a visceral pain.
3. The method of claim 2 , wherein said treatment comprises treatment of a trigeminal pain.
4. The method of claim 2 , wherein said treatment comprises treatment of a somatic pain.
5. The method of claim 2 , wherein said treatment comprises treatment of a neuropathic pain.
6. The method of claim 2 , wherein said treatment comprises treatment of a visceral pain.
7. The method of claim 1 , wherein said treatment comprises treatment of an acute pain or a chronic pain.
8. The method of claim 7 , wherein said treatment comprises treatment of an acute pain.
9. The method of claim 7 , wherein said treatment comprises treatment of a chronic pain.
10. The method of claim 1 , wherein the pain is a craniofacial pain or a head pain.
11. The method of claim 10 , wherein the craniofacial pain or the head pain is caused by temporomandibular joint disorder (TMJ), migraine or trigeminal neuralgia.
12. The method of claim 11 , wherein the craniofacial pain or the head pain is caused by temporomandibular joint disorder (TMJ).
13. The method of claim 11 , wherein the craniofacial pain or the head pain is caused by migraine.
14. The method of claim 11 , wherein the craniofacial pain or the head pain is caused by trigeminal neuralgia.
15. The method of claim 1 , wherein N/OFQ is administered as a pharmaceutical composition.
16. The method of claim 15 , wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients, adjuvants, diluents or stabilizers.
17. The method of claim 15 , wherein the pharmaceutical composition further comprises at least one protease inhibitor and/or at least one absorption enhancer.
18. The method of claim 1 , wherein the administration results in reduction of a pain rating on the VAS of 30% or more.